ABSTRACT
Background Exposure to O3 has been associated with increased risk of exacerbations of asthma, but the underlying mechanisms are not well studied. We hypothesized that O3 exposure would enhance airway inflammatory responses to allergen and the GSTM1 null genotype would modulate this enhancement.
Procedures In a cross-over design, 10 asthmatic subjects (50% with GSTM1 null genotype) who had specific sensitization to Dermatophagoides pteronyssinus (DP) were exposed to 160 ppb O3 or filtered air (FA) control for 4 h with intermittent exercise on two separate days at least three weeks apart. 20 h post-exposure, endobronchial challenge with DP allergen, and sham normal saline (NS) instillation, were performed in two separate lung lobes. Six h later, a second bronchoscopy was performed to collect bronchoalveolar lavage (BAL) fluid from the DP- and NS-challenged lobes for analyses of cellular and biochemical markers of inflammation. Multiple variable regression was used to compare cell and cytokine responses across the four exposure groups (FA-NS, O3-NS, FA-DP, O3-DP). Effect modification by GSTM1 genotype was assessed in stratified regressions.
Main Findings BAL eosinophil and lymphocyte counts were increased in segments challenged with DP compared to segments that received sham challenges (p<0.01). DP challenge compared to sham challenge also caused a significant increase in BAL concentrations of the Th2 cytokines IL-4, IL-5, IL-10, and IL-13 (p<0.03 for all comparisons). O3 exposure did not significantly affect BAL cells or cytokine levels although BAL neutrophil count with DP challenge was non-significantly higher after O3 compared to after FA exposure (p<0.11). Compared to GSTM1-present subjects, GSTM1-null subjects had significantly reduced inflammatory responses including lower eosinophil (p<0.041) and IL-4 (p<0.014) responses to DP challenge after O3 exposure.
Conclusions O3 appears to have mixed effects on allergen-induced airway inflammation. While O3 did not cause a clear differential effect on airway cellular or cytokine responses to allergen challenge, those responses did appear to be modulated by the antioxidant enzyme, GSTM1, as evident by the attenuation of airway inflammatory responses to allergen after O3 exposure in the absence of the gene.
HIGHLIGHTS
Ozone may increase risk of asthma exacerbation but the exact mechanisms are not clear.
Susceptibility to ozone-induced airway inflammation may be associated with GSTM1 genotype.
Ozone may enhance allergen-induced airway recruitment of neutrophils.
The GSTM1 null mutation may decrease both eosinophil and cytokine allergic airway responses after O3 exposure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding:California Air Resources Board (CARB) Contract 03-315, NIH/NHLBI K23 HL083099, and NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of California San Francisco Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: California Air Resources Board (CARB) Contract 03-315, NIH/NHLBI K23 HL083099, and NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131.
The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of either CARB or the NIH.
Declarations of interest: none
Mehrdad Arjomandi: Conceptualization, Methodology, Investigation, Data curation, Formal analysis, Visualization, Writing - review & editing; Hofer Wong: Investigation; Rachel Tenney: Investigation; Nina Holland: Investigation; John Balmes: Conceptualization, Methodology, Funding acquisition, Investigation, Writing - original draft
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
